Nexium could face early generic challenge, say analysts

Share this article:
AstraZeneca's Nexium could face generic competition much sooner than expected, and would-be investors should be wary, said brokerage firm Sanford C. Bernstein in an analyst note.

The PPI, AstraZeneca's top-selling drug and one of the biggest brands in prescription drug advertising, isn't due to lose patent protection until 2018, but given Teva's surprise “at risk” generic launch against Wyeth's Nexium rival Protonix in December, Bernstein analysts say it's even odds that Nexium could face generic competition sooner – perhaps as early as April.

Ranbaxy, Bernstein notes, has “first filer” status against Nexium, and their 30-month stay ends in April. Teva's 30-month stay ends in July. The Feb. 25 note speculates that Ranbaxy and Teva could team up for an April launch.

An early generic launch against Nexium could hit AstraZeneca's earnings per share by 11% annually, the firm projected, and Merck's EPS by around 5%. Merck collects a 27% royalty on US sales of the drug, which boasts US sales of around $3 billion annually.

From Q1 2006 through Q3 2007, consumer advertising for the brand totaled $230 million, according to TNS Media Intelligence – placing Nexium behind only Ambien and Lunesta in DTC spending. Saatchi & Saatchi Healthcare Communications handles both consumer and professional advertising for the brand.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...